CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chung, Alexander H.
Leisner, Tina M.
Dardis, Gabrielle J.
Bivins, Marissa M.
Keller, Alana L.
Parise, Leslie V.
Funding for this research was provided by:
North Carolina Biotechnology Center (R41CA200189)
Graduate School, University of North Carolina at Chapel Hill
20 September 2018
29 January 2019
4 February 2019